Nyxoah S.A. (EBR: NYXH)
Belgium
· Delayed Price · Currency is EUR 7.82
-0.18 (-2.25%)
Nov 19, 2024, 9:00 AM CET
Nyxoah Company Description
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions.
The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah S.A.
| Country | Belgium |
| Founded | 2009 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 147 |
| CEO | Olivier Taelman |
Contact Details
Address: Rue Edouard Belin 12 Mont-Saint-Guibert, 1435 Belgium | |
| Phone | 32 10 22 23 55 |
| Website | nyxoah.com |
Stock Details
| Ticker Symbol | NYXH |
| Exchange | Euronext Brussels |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | BE0974358906 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Olivier Taelman | Chief Executive Officer and Executive Director |
| Robert Taub MBA | Co-Founder and Chairman |
| Loic Moreau | President of International |
| John Landry | Chief Financial Officer |
| Bruno Onkelinx | Chief Technology Officer |
| Mikaela Kirkwood | Corporate Communication and Investor Relations Manager |
| An Moonen | General Counsel |
| Inge Vanwittenbergh | Global Human Resource Director |
| Remi Renard | Chief of Staff |
| Jeyakumar Subbaroyan | Chief Clinical Officer |